. "Methodology of cost-effectiveness analysis (CEA) on the example of temozolomide and intrathecally applied carmustine in patients with glioblastoma multiforme"@en . . "Cost effectiveness analysis (CEA); glioblastoma multiforme"@en . . . . . . "I, V" . "Metodika CEA na p\u0159\u00EDkladu temozolomidu a intrat\u00E9k\u00E1ln\u011B aplikovan\u00E9ho karmustinu u pacient\u016F s glioblastoma multiforme" . "4"^^ . "RIV/00209805:_____/11:#0000221" . "6"^^ . . "Metodika CEA na p\u0159\u00EDkladu temozolomidu a intrat\u00E9k\u00E1ln\u011B aplikovan\u00E9ho karmustinu u pacient\u016F s glioblastoma multiforme" . "RIV/00209805:_____/11:#0000221!RIV12-MZ0-00209805" . . "Metodika anal\u00FDzy n\u00E1hledov\u00E9 efektivity (CEA) mus\u00ED ur\u010Dovat volbu l\u00E9\u010Debn\u00E9ho p\u0159\u00EDstupu (tzv. kompar\u00E1toru), se kter\u00FDm novou alternativu porovn\u00E1v\u00E1me, perspektivu hodnocen\u00ED (zda prov\u00E1d\u00EDme anal\u00FDzu z pohledu poskytovatele p\u00E9\u010De, pl\u00E1tce p\u00E9\u010De, pacienta nebo cel\u00E9 spole\u010Dnosti), strukturovan\u00E9 n\u00E1klady sledovan\u00FDch l\u00E9\u010Debn\u00FDch alternativ, relevantn\u00ED klinick\u00E9 v\u00FDsledky, p\u0159\u00EDpadnou zm\u011Bnu n\u00E1klad\u016F v pr\u016Fb\u011Bhu hodnocen\u00E9ho obdob\u00ED, dopad anal\u00FDzy senzitivity na v\u00FDsledky a tak\u00E9 limity anal\u00FDzy v\u010Detn\u011B mo\u017Enosti zobecn\u011Bn\u00ED v\u00FDsledk\u016F. Tento \u010Dl\u00E1nek si klade za c\u00EDl popsat v hrub\u00FDch rysech tyto z\u00E1kladn\u00ED komponenty CEA a zamyslet se nad probl\u00E9my, kter\u00E9 autor anal\u00FDzy mus\u00ED \u0159e\u0161it." . "Metodika CEA na p\u0159\u00EDkladu temozolomidu a intrat\u00E9k\u00E1ln\u011B aplikovan\u00E9ho karmustinu u pacient\u016F s glioblastoma multiforme"@cs . . "Kandrnal, V." . "211888" . . "Methodology of cost-effectiveness analysis (CEA) on the example of temozolomide and intrathecally applied carmustine in patients with glioblastoma multiforme"@en . "Metodika CEA na p\u0159\u00EDkladu temozolomidu a intrat\u00E9k\u00E1ln\u011B aplikovan\u00E9ho karmustinu u pacient\u016F s glioblastoma multiforme"@cs . "Metodika anal\u00FDzy n\u00E1hledov\u00E9 efektivity (CEA) mus\u00ED ur\u010Dovat volbu l\u00E9\u010Debn\u00E9ho p\u0159\u00EDstupu (tzv. kompar\u00E1toru), se kter\u00FDm novou alternativu porovn\u00E1v\u00E1me, perspektivu hodnocen\u00ED (zda prov\u00E1d\u00EDme anal\u00FDzu z pohledu poskytovatele p\u00E9\u010De, pl\u00E1tce p\u00E9\u010De, pacienta nebo cel\u00E9 spole\u010Dnosti), strukturovan\u00E9 n\u00E1klady sledovan\u00FDch l\u00E9\u010Debn\u00FDch alternativ, relevantn\u00ED klinick\u00E9 v\u00FDsledky, p\u0159\u00EDpadnou zm\u011Bnu n\u00E1klad\u016F v pr\u016Fb\u011Bhu hodnocen\u00E9ho obdob\u00ED, dopad anal\u00FDzy senzitivity na v\u00FDsledky a tak\u00E9 limity anal\u00FDzy v\u010Detn\u011B mo\u017Enosti zobecn\u011Bn\u00ED v\u00FDsledk\u016F. Tento \u010Dl\u00E1nek si klade za c\u00EDl popsat v hrub\u00FDch rysech tyto z\u00E1kladn\u00ED komponenty CEA a zamyslet se nad probl\u00E9my, kter\u00E9 autor anal\u00FDzy mus\u00ED \u0159e\u0161it."@cs . "2"^^ . . "Postgradu\u00E1ln\u00ED medic\u00EDna" . . "Demlov\u00E1, Regina" . . "http://www.zdn.cz/clanek/postgradualni-medicina/metodika-cea-na-prikladu-temozolomidu-a-intratekalne-aplikovaneho-karmustinu-u-pacientu-s-glioblastoma-multiforme-461808" . "13" . "CZ - \u010Cesk\u00E1 republika" . "8" . "[13DC77188610]" . "Lakom\u00FD, Radek" . "Cost effectiveness analysis (CEA) is together with cost minimization analysis, cost utility analysis and cost benefit analysis one of the main tools of pharmaco-economics. The main aim of CEA is to quantify and compare costs of two or more treatment alternatives, usually described in monetary units and related to the natural health units, e. g. change of blood pressure, time to disease progression, blood cholesterol level change, quality of life, etc. Methodology of CEA should encompass the appropriate treatment options alternatives, perspective (point of view of e. g. a healthcare provider, healthcare payer, patient or whole society), an assessment of costs as well as appropriate clinical outcomes of all alternatives, change of costs during the assessed period, a sensitivity analysis and description of all limitations including possibility of results generalization. The aim of this article is to describe basic characteristics of CEA and highlight issues that author must face and resolve in the process of carrying out the analysis."@en . . . "1212-4184" .